|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
109.92/-1.40
|
企業價值
88.52M
|
資產負債 |
每股賬面淨值
-2.21
|
現金流量 |
現金流量率
--
|
損益表 |
收益
7.19M
|
每股收益
0.77
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/16 00:27 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology. |